This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (15)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. C. SWARTZWELDER, Ph.D.; J. P. MUHLEISEN, M.D.; S. H. ABADIE, B.S.; W. W. FRYE, Ph.D., M.D.; C. A. JONES, M.D., D.Sc.; P. E. ROBERTSON; J. F. HEBERT

AMA Arch Intern Med. 1958;101(3):658-661.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

Data presented in this paper provide evidence of the anthelmintic activity and therapeutic effectiveness of 3,3'-diethylthiadicarbocyanine iodide (dithiazanine, Compound 01748) against Strongyloides stercoralis infections in humans and experimental infections with Strongyloides ratti in rats. Prior to this study, a large number of other drugs were evaluated by us for anthelmintic activity against murine and human strongyloidiasis. None of the compounds employed in our previous investigations gave evidence of significant activity or cure of strongyloidiasis in either host. There is a definite need for effective therapeutics for strongyloidiasis. Stoll¹ estimated that there were approximately 35,000,000 infections with S. stercoralis in the world. In one hospital in New Orleans in recent years there have been several hundred patients with strongyloidiasis. Jones ² has described precisely the clinical significance and characteristics of strongyloidiasis. Frequently the infection persists for many years in man, and on rare occasions it may prove fatal.

Interpretation . . . [Full Text PDF of this Article]

Author Affiliations
Med.; New Orleans

Louisiana State University School of Medicine and Veterans' Administration Hospital.

Footnotes
Submitted for publication Aug. 12, 1957.

The drug employed in this study, dithiazanine (compound 01748), was provided by Eli Lilly and Company.

The statements and conclusions published by the authors are the results of their own studies and do not necessarily reflect the opinion or policy of the Veterans Administration.

This investigation was supported in part by research Grant E-543 from the National Institute of Allergy and Infectious Diseases, of the National Institutes of Health, Public Health Service.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?